Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine <it>vs </it>single and combination treatments of uncomplicated falciparum in sub-Saharan Africa by Zwang Julien et al.
RESEARCH Open Access
Comparing changes in haematologic parameters
occurring in patients included in randomized
controlled trials of artesunate-amodiaquine vs
single and combination treatments of
uncomplicated falciparum in sub-Saharan Africa
Julien Zwang
1*, Jean-Louis Ndiaye
2, Abdoulaye Djimdé
3, Grant Dorsey
4, Andreas Mårtensson
5,6, Corine Karema
7
and Piero Olliaro
8,9
Abstract
Background: Artesunate-amodiaquine (AS&AQ) is a widely used artemisinin combination therapy (ACT) for
falciparum malaria. A comprehensive appreciation of its effects on haematology vs other anti-malarials is needed in
view of potential safety liabilities.
Methods: Individual-patient data analysis conducted on a database from seven randomized controlled trials
conducted in sub-Saharan African comparing AS&AQ to reference treatments in uncomplicated falciparum malaria
patients of all ages. Haematologic values (white cells total and neutrophil counts, haemoglobin/haematocrit,
platelets) were analysed as both continuous and categorical variables for their occurrence, (severity grade 1-4) and
changes during follow-up. Risks and trends were calculated using multivariate logistic random effect models.
Results: 4,502 patients (72% < 5 years old), from 13 sites in nine countries with 28-day follow-up were treated
with AS&AQ (45%) or a comparator (other forms of ACT accounted for 27%, other combination 12%, mono-
therapies 16%). Pre-treatment leucopaenia (3%) and neutropaenia (6%) were infrequent; anaemia was common
(39%). The treatment-emergent adverse events incidence (TEAE = condition not present or less severe pre-
treatment) was 11% for neutropaenia, 6% for thrombocytopaenia with AS&AQ and not different from treatment
groups; anaemia was higher with AS&AQ (20%) or other forms of ACT (22%) than in non-artemisinin groups (4%, p
= 0.001). Multivariate analysis showed that the risk of anaemia, thrombocytopaenia, and leucopaenia decreased
with follow-up time, while neutropaenia increased; the risk of anaemia and thrombocytopaenia increased with
higher baseline parasitaemia and parasitological reappearance. White cells total count was not a good surrogate
for neutropaenia. No systematic significant difference between treatments was detected. Older patients were at
lower risks.
Conclusion: The effects of AS&AQ on haematologic parameters were not different from those of other anti-
malarial treatments used in sub-Saharan Africa. This analysis provides the basis for a broader evaluation of
haematology following anti-malarial treatment. Continuing monitoring of haematologic safety on larger databases
is required.
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Artemisinin-based combinations (ACT)-the treatment of
choice for uncomplicated Plasmodium falciparum
malaria [1]-are generally safe and well tolerated, but
haematologic toxicity remains of potential concern, in
particular for treatments containing amodiaquine. Neu-
tropaenia and agranulocytopaenia have been reported in
the past with intermittent (weekly) doses of amodia-
quine for malaria prophylaxis; the reported rate of ser-
ious events (blood dyscrasias) in the UK was 1:2,100
users, with a fatality rate of 1:75,000 [2]. It has been
shown that agranulocytosis is unlikely to occur when
amodiaquine is used for treatment (as opposed to pro-
phylaxis), but it is not easy to derive information from
published information. A meta-analysis of comparative
and non-comparative trials of amodiaquine for treating
malaria did not show a particular risk of neutropaenia
associated with amodiaquine [3]; other systematic
reviews have little safety data, especially on haematolo-
gic toxicity [4]. Neutropaenia has been reported after
administration of treatment doses of amodiaquine, alone
or in combination with artesunate [5-8], and also with
artesunate with a dose-dependent risk [9].
Artesunate combined with amodiaquine (AS&AQ) is
the second most widely used ACT, adopted as first-line
treatment in 18 countries. Over time, AS&AQ has been
available in a non-fixed formulation (AS+AQ, as either a
loose combination or in blister packs produced by dif-
ferent manufacturers), and more recently, as a fixed-
dose, WHO-prequalified, co-formulation (ASAQ).
Although serious adverse events following ACT seem
to be uncommon, very few trials compared the haema-
tologic variations between treatments. Two randomized
controlled trials (RCT) conducted in sub-Saharan Africa
reported no difference in neutropaenia between artesu-
nate-amodiaquine and artemether-lumefantrine [10,11].
Safety in general, and laboratory data in particular, are
underreported in malaria trials; risk should be assessed
comparatively; databases should be large enough and
representative of the spectrum composition of patients
and conditions. Limited information can be derived
from aggregated data, and individual patient data are
best suited for such assessment. The widespread use of
these anti-malarial combinations calls for a comprehen-
sive synthesis of available individual patient’s haematolo-
gic data.
Methods
Data on age, parasitaemia, haematologic parameters
(white blood cells total counts (WCC), neutrophil and
lymphocyte counts, haemoglobin or haematocrit and
platelet counts), treatment and treatment outcome were
extracted from a database of randomized controlled
trials (RCT) including AS&AQ groups conducted in
sub-Saharan Africa with 28-day follow-up (26 trials in
16 countries and 33 sites with 11,700 participants). Data
were censored when patients dropped out or had recur-
rent P. falciparum. Details on these studies are provided
elsewhere [12].
The criteria for selection of the seven RCT were based
o nt h ep r e s e n c eo fh a e m a t o l o g i cd a t a( n=4 , 5 0 2 )a n d
comparators including monotherapies: amodiaquine
(AQ) or artesunate (AS) alone or other artemisinin
combination therapy: artemether-lumefantrine (AL),
artesunate plus sulphadoxine/pyrimethamine (AS+SP),
dihydroartemisinin-piperaquine (DP) or non-artemisinin
containing combinations (AQ+SP) [5,13-17](Table 1).
Analysis involved 4,502 patients: 10,677 records in
3,829 patients at various time points for WCC; 8,232
records in 3,069 patients for neutrophils; 12,888 records
in 4,276 patients for haemoglobin; and 3,514 records in
1,419 patients for platelets.
Treatments
AS&AQ treatment regimens
AS&AQ products were either loose (AS+AQ) or fixed-
dose co-formulations (ASA Q ) .T h el o o s eA S + A Qw a s
dosed based on body weight, while the co-formulated
ASAQ was based on age and weight range.
The proportion of patients treated with AS&AQ was
45% (2,038/4,502) of which 31% (624/2,038) were trea-
ted with a fixed-dose ASAQ combination (Coarsucam™,
Winthrop), and 69% (1,412/2,038) were treated with
loose combinations: in Gabon, Kenya and Uganda was
AS (Arsumax™ 50 mg, Sanofi) and AQ (Camoquine™
200 mg, Parke-Davis); in Zanzibar: AS (Plasmotrim™
100 mg, Mepha) and AQ (Flavoquin™,1 5 3m g ,R o u s -
sel); in Rwanda (Arsumax™, Sanofi [15]), and AQ and
AS (Dafra Pharma [17]).
The loose combination target dose was AS 12 mg/kg
over three days and AQ 30 mg/kg over 3 days, except in
Uganda where AQ was given at 25 mg/kg (10 mg/kg on
Days 0 and 1 then 5 mg/kg on Day 2). The fixed-dose
combinations of ASAQ (Coarsucam™,W i n t h r o p )w e r e
available as two-and three-strength products given by
age. The fixed-dose combination was given either once
or twice a day. For the two-strength fixed-dose combi-
nation ASAQ (paediatric AS 25 mg+AQ 67.5; adult AS
100 mg+AQ 270 mg, dose ratio = 2.7), the dosing cate-
gories were: (i) 0-1 months: 1/2 paediatric; (ii) 2-11
months: 1 paediatric; (iii) 1-6 years: 2 paediatric; (iv) 7-
13 years: 1 adult; and (v) ≥ 14 years: 2 adults. For the
three-strength ASAQ, age- and weight-based doses were
administered once-a-day for three days: one tablet/day
for children up to 13 years of age (≤ 35 kg) or two
tablets/day for adolescents aged 14 years and above and
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Page 2 of 11adults (≥ 36 kg). Doses available were: infants (two to 11
months) received AQ 25 mg/AS 67.5 mg; young chil-
dren (one to 4 years) received AQ 50 mg/AS 135 mg;
children (six to 13 years) received one tablet/day of AQ
100 mg/AS 270 mg, and adults (14 years or more)
received two tablets (AQ 100 mg/AS 270 mg) per day.
Other forms of ACT
Patients treated with other forms of ACT accounted for
27% (1,228/4,502) of the total: 728 with AL (20 mg arte-
mether/120 mg lumefantrine given according to weight
as one (5-14 kg), two (15-24 kg), three (25-34 kg), and
four 4 (≥ 35 kg) tablets given twice daily for three days);
251 with DP (around 2.3 mg/kg/day dihydroartemisinin
and 18.4 mg/kg for three days); and 249 with AS+SP
(AS 4 mg/kg/day; SP 25 mg/kg of sulphadoxine and
1.25 mg/kg/of pyrimethamine administered in a co-for-
mulated tablet (SP) as a single dose).
Non-ACT combinations
Patients treated with a non-artemisinin containing com-
bination accounted for 12% (527/4,502): AQ+SP (AQ 10
mg/kg/day for three days and SP 25 mg/kg of sulpha-
doxine and 1.25 mg/kg/of pyrimethamine administered
in a co-formulated tablet (SP) as a single dose).
Monotherapies
AQ only (10% of patients) was given at 10 mg/kg/day
for three days; AS only (6% of patients) was given at a
total dose of 12 mg/kg over five days.
Haematology
The grading of all paediatric haematological values was
derived from international standards [18-20].
Leucopaenia was defined as white blood cell counts
(WCC) < 3 × 10
9/L; mild/moderate was 3 × 10
9/L to 2
×1 0
9/L, and severe/very severe leucopaenia was < 2 ×
10
9/L (grade 3: 1.9 × 10
9/L to 1 × 10
9/L and 4: < 1 ×
10
9/L).
Neutropaenia was defined as neutrophil counts < 1.20
×1 0
9/L; mild/moderate neutropaenia ranged from 1.19-
0.40 × 10
9/L (grade 1: 1.19 × 10
9/L to 0.75 × 10
9/L and
2: 0.74 × 10
9/L to 0.40 × 10
9/L), and severe/very severe
neutropaenia was < 0.40 × 10
9/L (grade 3: 0.39 × 10
9/L
to 0.25 × 10
9/L and 4: < 0.25 × 10
9/L).
For anaemia the cut off was set at haematocrit < 30%
or haemoglobin < 10 g/dL and was categorized as: mild/
moderate from 9.9-8.0 g/dL of haemoglobin (grade 1:
9 . 9g / d lt o9 . 0g / d La n d2 :8 . 9g / d Lt o8g / d L ) ,a n d
severe/very severe < 8 g/dL of haemoglobin (grade 3: 8
g/dL to 5 g/dL and 4: < 5 g/dL).
Thrombocytopaenia was defined as platelets count <
150 × 10
9/L; mild/moderate ranged 150-50 × 10
9/L
(grade 1: 149 × 10
9/L to 75 × 10
9/L and 2: 74 × 10
9/L
to 50 × 10
9/L), and severe/very severe thrombocytopae-
nia < 50 × 10
9/L (grade 3: 49 × 10
9/L to 20 × 10
9/L and
4: < 25 × 10
9/L).
Recovery from an abnormal condition was defined for
leucopaenia as WCC becoming ≥3×1 0
9/L, for neutro-
paenia as ≥1.2 × 10
9/L, for anaemia as haematocrit
becoming ≥30% or haemoglobin ≥10 g/dL, for thrombo-
cytopaenia as platelets ≥150 × 10
9/L.
A haematological adverse event (AE) was defined as
the occurrence of an abnormal value (grade 1 or more,
as defined above) after treatment start independent of
the pre-treatment value. In this analysis, all visits were
considered, thus a subject could have multiple AEs.
A treatment-emergent AE (TEAE) expresses the wor-
sening of the condition-i.e. any occurrence of an abnor-
mal value at any follow-up visit (days 7 through 28) as
compared to baseline in patients who either had a nor-
mal condition pre-treatment or an abnormal value that
was of lower grade than post-treatment. Drug-event
relationship could not be attributed in the present
analysis.
Statistical analysis
Haematologic changes were analysed between Days 0-7,
0-14, and 0-28 using t-student paired analysis and pre-
sented as relative difference (Day 0 as the reference). In
each RCT, the patients’ paired differences were com-
pared between treatment groups using the Mann-Whit-
ney rank test. Categorical data were compared using a
Table 1 Number of patients recruited by treatment group and study
RCT Location Reference ACT Mono-therapy non-ACT Total
AS&AQ AL DP AS+SP AQ AS AQ+SP
ACT vs monotherapy Multicentre [5] 306 307 613
Rwanda [17] 158 150 308
Mali [13] 252 249 252 753
ACT vs ACT and non-ACT Uganda [14] 242 217 269 728
Rwanda [15] 252 251 258 761
Multicentre [16] 626 311 937
Zanzibar [10] 202 200 402
Total 2038 728 251 249 457 252 527 4502
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Haenszel chi-square test stratified by site and the com-
parison presented by odds ratio (OR), as appropriate.
During the 28-day follow-up, the timing of post-treat-
ment haematologic assessments varied across studies
(Table 2), therefore an adjustment for time (day of
observation) was included in the multivariate analysis.
All available haematologic values for every patient were
considered. A random intercept for each individual was
included when the Lagrange multiplier (LM) test [21]
was significant for heterogeneity in multivariate logistic
regression. These multivariate analyses assessed the risks
for leucopaenia, neutropaenia, anaemia, and thrombocy-
topaenia (analysed as binary variables) during follow-up.
The adjusted risks (AOR) of the above conditions were
assessed over time (continuous, in days), according to
the patients’ age (continuous, in years), parasitaemia
(continuous, in parasites/μL, log-transformed), parasito-
logical reappearance (or treatment outcome, including
recrudescence and re-infections; binary, at the exact day
of occurrence) along with the interaction of age and
parasitaemia, as well as the potential effects of the var-
ious treatments in each RCT.
For relative differences, confidence intervals (CI) were
calculated using the normal distribution. All CIs were
calculated at 95% (95%CI) and comparisons considered
significant when p < 0.05. Data were analysed using
Stata v10 (Stata Corp.).
Ethical issues
All the studies had been approved by the relevant ethics
and institution review committees [5,10,13-17].
Results
The main baseline characteristics of the patients
enrolled are displayed in Table 3. Seventy-two percent
(72%, range 32-100%) were children under five years of
age from 13 sites in nine countries. The geometric
mean pre-treatment parasitaemia was 18,425 overall and
ranged from 9,203 to 30,988 parasites/μL, by site. At
presentation, leucopaenia and neutropaenia were infre-
quent (3% and 6% respectively), while
thrombocytopaenia and anaemia were found in 32% and
49% of subjects (Table 4).
Frequency of events
During follow-up (any time, all observations), abnormal
values occurred in 2% (224/10,677) for leucopaenia, 8%
(621/8,232) for neutropaenia, 40% (5,102/12,888) for
anaemia, 19% (685/3,514) for thrombocytopaenia.
Of all the above events, the proportion of those that
were severe (grade 3 and 4) was 8% (19/224) for leuco-
paenia, 3% (18/621) for neutropaenia, 28% (1,412/5,102)
for anaemia, and 15% (100/685) for thrombocytopaenia.
Overall, the proportion of patients with severe leuco-
paenia was lower on AS&AQ than other treatments (p
= 0.023 stratified by site, accounted for by a higher fre-
quency with AL in Zanzibar) while no difference was
detected for severe neutropaenia, severe anaemia, and
severe thrombocytopaenia (p =0 . 8 0 4 ,p = 0.800, p =
0.470, respectively, stratified by site).
Haematological treatment emergent adverse events
(TEAEs)
The occurrence of TEAEs for neutropaenia, anaemia
and thrombocytopaenia could be calculated for 1192,
2063 and 1375 patients respectively who had both base-
line and follow-up values (through Day 28 for neutro-
paenia and anaemia, and Day 14 for thrombocytopaenia)
(Table 5). In those treated with AS&AQ, the overall
incidence of TEAEs was 11%, 20% and 6%, respectively.
No difference was observed for neutropaenia between
AS&AQ compared to other artemisinin treatments (p =
0.475) or non-artemisinin treatments (p = 0.642), and
for thrombocytopaenia compared to other artemisinin
treatments (p = 0.734). In contrast with the incidence of
TEAE for anaemia that was higher in AS&AQ or other
artemisinin groups compared to non-artemisinin treat-
ments (p = 0.001, for both comparisons).
Descriptive paired analysis (baseline vs follow-up)
Single-agent comparators
Amodiaquine (AQ) mono-therapy (Additional file 1)
T w oR C T sc o m p a r i n gA S & A Q( n=4 6 4 )t oA Qa l o n e
Table 2 Follow-up timing per study and haematologic parameters
Location Reference N White blood cell counts (WCC) Neutrophils Haemoglobin Platelets
Multi-centre [5] 613 D0 D0, D28
Multi-centre [16] 937 D0, D7, D28 D0, D7, D28 D0, D28
Mali [13] 753 D0, D7, D14, D28 D0, D7, D14, D28 D0, D7, D14
Rwanda [17] 308 D0, D14, D28
Rwanda [15] 761 D0, D14 D0, D14 D0, D14
Uganda [14] 728 D0, D14 D0, D14 D0, D14 D0, D14
Zanzibar [10] 402 D0, D7, D14, D21, D28 D0, D7, D14, D21, D28 D0, D7, D14, D21, D28
Legend: D day
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increased risk when adding AS to AQ. There was:
i. no significant variation in WCC through Day 28 in
both groups, and no difference in variations between
AS&AQ and AQ (p = 0.882). In each group one
patient was leucopaenic on admission and recovered;
one in the AQ group became leucopaenic and none
in the AS&AQ.
ii. a significant decrease in neutrophils by Day 7 and
14 (-17% and -37%, no data on Day 28) for AS&AQ
and on Day 7 for AQ alone (-21%), but no difference
between the two groups; there was one neutropaenic
patient in the AQ group who recovered and none in
the AS&AQ group. Only one patient from the
AS&AQ group became neutropaenic.
iii. a significant increase in haemoglobin in both
groups on Days 14 and 28 (final gain 13% and 10%,
Table 3 Age and parasitaemia on admission by site
N Parasitaemia (μ/L) Age (year)
Site total geometric mean Under five years old median minimum maximum
Cameroon 166 24627 44% 6.2 1.0 65.0
Gabon 216 22597 42% 5.4 1.3 10.8
Kenya 397 30988 80% 2.0 .5 11.0
Madagascar 178 9203 32% 7.5 1.4 53.1
Mali-Bancouna 201 22386 54% 4.7 .9 24.3
Mali-Bougoula 753 15468 91% 2.5 .6 13.7
Rwanda-kicukiro 313 27938 99% 3.0 .6 5.0
Rwanda-mashesha 391 18462 99% 3.0 .5 5.0
Rwanda-rukara 365 33615 100% 2.0 .5 4.9
Senegal 392 19142 50% 5.0 .9 64.0
Uganda-Kampala 728 10552 37% 6.1 1.1 11.5
Zanzibar-Kivunge 297 16500 97% 2.5 .5 6.5
Zanzibar-Micheweni 105 16777 99% 2.1 .5 5.0
Total 4502 18425 72% 3.4 .5 65.0
Table 4 Haematology on admission by site
WCC(*10
9/L) Neutrophils(*10
9/L) Haemoglobin (g/dL) Platelets(*10
9/L)
Site N mean SD n Leuco-
poenia
N mean SD n Neutro-
paenia
N Mean SD n Anae-
mia
N mean SD n Throm-
bocyto-
paenia
Cameroon 166 7.5 1.7 0 0% 165 4.0 1.4 3 2% 166 12.1 1.4 153 8%
Gabon 216 7.8 3.0 2 1% 207 3.7 2.4 16 8%
Kenya 41 9.6 3.7 0 0% 41 6.2 3.0 0 0% 397 9.3 2.0 155 61%
Madagascar 178 7.1 3.0 0 0% 167 4.6 2.7 1 1% 178 11.5 2.3 145 19%
Mali-
Bancouna
201 9.4 3.7 1 0% 194 6.2 3.1 1 1% 200 9.9 1.6 99 51%
Mali-
Bougoula
752 10.4 4.4 4 1% 752 10.2 1.8 424 44% 697 180 93 264 38%
Rwanda-
kicukiro
222 6.7 2.6 5 2% 222 3.7 2.0 10 5% 312 10.8 2.0 222 29%
Rwanda-
mashesha
269 5.4 1.7 0 0% 269 3.0 1.3 5 2% 391 10.1 1.4 232 41%
Rwanda-
rukara
270 4.0 1.6 80 30% 270 1.8 1.0 80 30% 365 10.3 1.8 242 34%
Senegal 392 9.3 4.5 2 1% 392 5.3 3.2 6 2% 392 10.1 2.4 209 47%
Uganda-
Kampala
721 7.6 3.6 8 1% 714 4.3 2.5 26 4% 728 11.6 1.3 646 11% 717 210 86 186 26%
Zanzibar-
Kivunge
297 6.2 3.1 18 6% 297 3.5 2.3 22 7% 297 8.8 1.5 66 78%
Zanzibar-
Micheweni
105 6.4 1.5 0 0% 105 3.0 1.2 0 0% 105 8.1 1.5 14 87%
Total 3830 7.8 3.9 120 3% 3043 4.0 2.6 170 6% 4283 10.3 2.0 2607 39% 1414 195 90 450 32%
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the two groups. The proportion of patients recover-
ing from anaemia by Day 28 was higher with AQ
(100%, 19/19) compared to AS+AQ (80%, 24/30, p =
0.037). The proportions of patients becoming anae-
mic were not different between AQ (6%, 3/49) and
AS&AQ (2%, 1/48, p = 0.385).
Artesunate (AS) mono-therapy (Additional file 1) One
RCT in Bougoula, Mali [13] comparing AS+AQ (n = 252)
to AS (n = 252) showed no increased risk (and a lower
risk of anaemia) when adding AQ to AS. There was:
i. a significant decrease in WCC in both groups
without difference between groups through Day 28;
there was no leucopaenic patient in both groups
during the follow-up.
ii. an increase in platelets in both groups without
difference between the two groups; 92% (11/12) in
the AS+AQ, and 75% (3/4) of the patients in the AS
group recovered (p = 0.802); 15% (4/27) and 40% (2/
5), respectively became thrombocytopaenic (p =
0.291).
iii. a significant transient decrease in haemoglobin by
Day 7 with AS+AQ and AS alike; by Day 28, the
gain in haemoglobin was greater in patients treated
with AS+AQ (+10%, 95%CI 7%-13%) than AS alone
(+7%, 95%CI 3%-7%, p = 0.031). The proportion of
patients recovering from anaemia was slightly higher
in AS+AQ (64%, 62/97) but not significantly differ-
ent from AS (55%, 51/93, p =0 . 2 0 3 ) .T h er i s ko f
becoming anaemic was higher with AS alone (15%,
18/120) than AS+AQ (7%, 9/138, OR 2.53, 1.09-5.87,
p = 0.026).
ACT comparators
Artesunate plus sulphadoxine/pyrimethamine (AS+SP)
(Additional file 1)
In Mali [13], AS+AQ (n = 252) was compared to AS+SP
(n = 249). No difference in WCC and platelets changes
was detected between the two groups during follow-up.
There was a significant transient decline in haemoglobin
by Day 7, and an increase in both groups through Day
28. The proportions of patients recovering from anaemia
by Day 28 in AS&AQ (64%, 62/97) compared to AS+SP
(62%, 67/108) and becoming anaemic in AS&AQ (7%,
9/138) compared to AS+SP (9%, 11/128) groups were
not different (p =0 . 7 8 1a n dp = 0.522, respectively, for
both comparisons).
Artemether-lumefantrine (AL) combination (Additional file 1)
Two RCTs comparing AS&AQ (n = 1070) to AL (n =
762) in seven sites [10,16] showed:
i. no change in WCC through Day 28 with AL and a
significant decrease with AS&AQ on Days 14 and 28
which was significantly greater than AL on Day 28
(-7%, 95%CI -4% to -10% vs 0%, 95%CI -5%-4%, p =
0.017); however, Day 28 WCC were not different
between the two groups (7.5 × 10
9/L and 7.4 × 10
9/L,
p = 0.402). The proportion of patients recovering
from leucopaenia on admission was not different
(AS&AQ = 100%, 10/10, AL = 90%, 9/10). In AS&AQ
< 1% (2/753), and 1% (5/461) of the patients in AL
group became leucopaenic (p = 0.092).
ii. a significant decrease in neutrophil counts with
both drugs at each time point (Days 7, 14 and 28)
which was significantly greater with AS&AQ than
AL on Days 14 and 28 (Day 28 variations were
-35%, 95%CI -30%-39% with AS&AQ vs -28%, 95%
CI -22% to -34% with AL, p =0 . 0 0 5 ) ;h o w e v e r ,D a y
28 neutrophil counts were not different (3.1 and 3.0,
p = 0.861). The proportion of patients recovering
from pre-treatment neutropaenia was similar in the
two groups (AS&AQ = 89%, 17/19, AL = 85%, 11/
13), as well as the proportion of patients becoming
neutropaenic (6%, 44/718 and 6%, 27/442, respec-
tively, p = 0.989).
iii. increased lymphocyte counts by over 40% in both
t h eA S & A Qa n dA Lg r o u p ;n od i f f e r e n c ei nv a r i a -
tions was detected between the two groups (for all
comparisons).
Table 5 Post-treatment haematologic adverse event (AE), treatment emergent AEs (TEAE), between Day 0 and Day 28
Condition Treatment Normal on admission TEAE (n) AE (n) TEAE AE
n % n N (total) n N (total) % %
Neutropaenia AS&AQ 1350 95% 144 1309 169 1323 11% 13%
Other artemisinin 919 95% 113 944 130 951 12% 14%
Non-artemisinin 602 92% 63 536 80 538 12% 15%
Anaemia AS&AQ 1141 59% 343 1750 693 1751 20% 40%
Other artemisinin 876 59% 328 1462 650 1462 22% 44%
Non-artemisinin 590 68% 29 717 82 718 4% 11%
Thrombocytopaenia AS&AQ 343 73% 28 463 39 463 6% 8%
Other artemisinin 436 64% 44 672 68 672 7% 10%
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b i ni nt h eA S & A Qc o m p a r e dt ot h eA Lg r o u p( p =
0.001), and a smaller increase by Day 14 (p = 0.049),
but by Day 28 no significant difference in haemoglo-
bin levels and the proportions of patients recovering
from anaemia (54%, 190/353 and 56%, 138/246, p =
0.582, respectively) or becoming anaemic (10%, 39/
409 and 8% 19/225, p = 0.648, respectively).
v. a significant increase in platelet counts of about
90% was observed in both groups. All patients recov-
ered in both groups with no patients developing
thrombocytopaenia.
Dihydroartemisinin-piperaquine (DP) (Additional file 1)
One RCT in Rwanda [15] comparing AS+AQ (n = 252)
to DP (n = 252) provided for haematologic data on
admission and Day 14.
i. WCC decreased significantly in the DP group but
not in the AS+AQ group, but the difference between
the two groups was statistically non-significant (p =
0.24). The proportion of patients recovering from
leucopaenia was higher in the AS+AQ (65%, 22/34)
than in the DP group (37%, 14/37, p =0 . 0 5 1 ) .H o w -
ever by Day 14, the prevalence rates of leucopaenic
patients were not different between groups (8%, 19/
247; 9%, 23/248, respectively, p = 0.528).
ii. the prevalence of neutropaenia on admission was
15% (38/252) in the AS+AQ group and 10% (24/
251) in the DP group (p = 0.060); at Day 14 the pre-
valence rates were also not different in the AS+AQ
group (15%, 37/247) compared to the DP group
(10%, 24/248, p = 0.073). A significant decrease in
neutrophils was observed in both groups. No differ-
ence was found between the two groups in the fall
in neutrophil counts (p = 0.800) or the proportions
of patients recovering (p = 0.720).
iii. Patients on AS+AQ had a faster haemoglobin
recovery (+10%, 95%CI 7%-13%) by Day 14 than
those treated with DP (+6%, 95%CI 3%-9%, p =
0.040). The proportion of patients recovering from
anaemia was not different between the two groups
(p = 0.45), but the risk of becoming anaemic with
DP (9%, 14/164) was higher (but not significantly
different) than with AS+AQ (4%, 6/160, OR 2.40,
95%CI 0.90-6.40, p = 0.073).
Non-artemisinin containing comparators
Amodiaquine plus sulphadoxine/pyrimethamine (AQ+SP)
(Additional file 1)
AS+AQ (n = 494) was compared to AQ+SP (n = 527) in
Rwanda and Uganda [14,15] where data were only avail-
able on admission and on Day 14. By day 14, WCC
slightly decreased with a significant decrease of neutro-
phils in both groups; haemoglobin and platelets signifi-
cantly increased in both groups. No difference was
detected between treatment groups for all haematologic
parameters studied (WCC, neutrophils, platelets).
Adjusted risks and trends
Large inter-individual differences in haematologic out-
comes were detected (p = 0.001, LM test) requiring the
use of random effects. All the following analysis used
multivariate logistic regression with random intercept
on individuals including all potential risk factors. During
the drug-free, post-treatment follow-up, it was found
that:
i. the risk of leucopaenia decreased (AOR 0.96, 95%
CI 0.94-0.98, p = 0.001), and was lower in older
patients (AOR 0.92, 95%CI 0.86-0.98, p = 0.013) and
higher in patients with higher baseline parasitaemia
(AOR 1.80, 95%CI 1.21-2.69, p = 0.001). No differ-
ence was detected between AS&AQ and comparator
treatments (AL, p =0 . 0 9 ;A S ,p =0 . 1 8 ;A S + S P ,p =
0.94; AQ+SP, p = 0.63) and treatment outcome (suc-
cess or parasitological reappearance) (p =0 . 1 1 ) .T h e
risk of severe (grade 3 and 4) leucopaenia was lower
in older patients (p = 0.031) and higher in patients
treated from AL (p = 0.031, all cases occurring in
Zanzibar) compared to AS&AQ.
ii. the risk of neutropaenia increased (AOR 1.03, 95%
CI 1.02-1.04, p = 0.001); older patients were at lower
risks (AOR 0.92, 95%CI 0.90-0.95, p = 0.001). No
difference was detected between AS&AQ and either
AQ (p = 0.16), AL (p = 0.56), AQ+SP (p = 0.98), or
DP (p = 0.08), or with respect to treatment outcome
(p = 0.67) or baseline parasitaemia (p =0 . 5 6 ) .N o
risk of severe neutropaenia (grade 3 and 4) was
detected.
iii. the risk of anaemia decreased (AOR 0.91, 95%CI
0.90-0.92, p = 0.001); patients with higher baseline
parasitaemia (AOR 1.53, 95%CI 1.30-1.80, p = 0.001)
and those experiencing recurrent parasitaemia (AOR
1.98, 95%CI 1.35-2.92, p =0 . 0 0 1 )w e r ea th i g h e r
risk, while older patients were at lower risk (AOR
0.67, 95%CI 0.64-0.70, p = 0.001). No difference was
detected between AS&AQ and either AL (p = 0.67),
AS + SP (p = 0.21), DP (p =0 . 6 9 ) ,A Q + S P( p =
0.22), AQ (p =0 . 4 8 ) ,o rA S( p =0 . 0 8 ) .N or i s ko f
severe anaemia (grade 3 and 4) was detected.
iv. the risk of thrombocytopaenia decreased (AOR
0.88, 95%CI 0.87-0.90, p = 0.001); older patients
(AOR 0.92, 95%CI 0.88-0.96, p = 0.001) were at
lower risks compared to younger patients; patients
with higher baseline parasitaemia (AOR 1.46, 95%CI
1.25-1.70, p = 0.001), treated in Uganda with AL
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(AOR 1.95, 95%CI 1.15-3.32, p = 0.013) were at
higher risks for thrombocytopaenia by Day 14. In
Mali, the risks of patients treated with AS (p = 0.64)
or AS+SP (p = 0.47) were not significantly different
from AS&AQ. Patients with a parasitological recur-
rence were at higher risks for thrombocytopaenia
(AOR 3.55, 95%CI 1.29-9.79, p = 0.014). There were
no data for AQ and DP. Similarly, the risk of severe
thrombocytopaenia dropped significantly during fol-
low-up (p = 0.025); younger patients (p = 0.001) and
patients treated with AS (p = 0.002) were at signifi-
cant higher risks compared to AS&AQ; no difference
was detected for the other treatments.
Discussion
Safety in general and laboratory data in particular are
under-reported in malaria, and limited information can
be derived from aggregated data meta-analyses. This
study obviates some of these shortcomings by collecting
and analysing individual data on a substantial number of
patients (about 4,500) from RCTs of loose or fixed-dose
artesunate-amodiaquine combinations (about 2,000) vs
single-agent and combination (artemisinin- or non arte-
misinin-containing) therapies. Studies were identified
through a systematic review of the literature conducted
in 2008 and contacting investigators who may be willing
to contribute their data [12]. A few additional compara-
tive trials for the treatment of acute falciparum malaria
in Sub-Saharan Africa [11,22,23] could not be included.
Ideally, a database to monitor safety should be estab-
lished and constantly updated.
In contrast with meta-analysis of aggregated study
reports, individual patient data permit analysis of hae-
matologic parameters as both continuous and categori-
cal (e.g. using common toxicity grades) variables, as well
as multivariate analyses including covariates such as
individuals, study site, age, baseline parasitaemia, treat-
ment outcome, and treatment group. As a result, con-
clusions can be drawn as to the contributions to
haematologic changes (both toxicity and recovery) of
either components of the combination (artesunate and
amodiaquine) both individually and together.
Overall, there appears to be no obvious, specific hae-
matologic risk systematically associated with artesunate-
amodiaquine as compared to single-agent and other
combination (with or without an artemisinin) therapies.
Knowledge of the haematologic changes occurring
during acute malaria and recovery is incomplete, limit-
ing our ability to analyse and understand drug-induced
changes. A recent analysis from this group of data in
African children under five years of age treated for P.
falciparum [24] showed that acute malaria (pre-
treatment) induced a moderate increase in white cells
counts (WCC, +5%) resulting from an increase in neu-
trophils (+43%) that was proportionally larger than the
decrease in lymphocytes counts (-16%); haemoglobin
and platelets decreased (-13% and -49%). Post-treatment,
although there was a small decrease in WCC, the risks
of leucopaenia decreased while the risk of neutropaenia
increased.
Differently from the above-cited study, the present one
had patients of all ages (although 72% were under 5
years old) and no lymphocyte counts. Six of the seven
trials of this analysis are inc o m m o nw i t ht h ep r e v i o u s
analysis [24]. Burkina Faso [6] was not included here
since the trial compared two ASAQ combinations, and a
study conducted in Rwanda comparing AS+AQ to AQ
was added [17]. However, as the present analysis was
n o tr e s t r i c t e dt oc h i l d r e nu nder five years of age, only
around half (54%, 2447/4502) of the patients were in
common in both analyses.
In the present study including also about one-third of
adults, acute malaria (pre-treatment) was associated
with a very low risk of leucopaenia (3%) and neutropae-
nia (6%); instead, anaemia (about 60%) and thrombocy-
topaenia (about one-third) were common. Also, older
patients were at lower risk for leucopaenia, neutropae-
nia, anaemia, and thrombocytopaenia, contrary to find-
ings in the narrower group of children under five years
of age, for whom no age-effect was apparent except for
anaemia [24].
Post-treatment, the risk of leucopaenia, anaemia and
thrombocytopaenia decreased, while the risk of neutro-
paenia increased over time. When interpreting this find-
ing, it should be noted that: (i) the risk post-treatment
includes the prevalence of all the events occurring
throughout the 28-day follow-up period and (ii) the
time trends (analysed as a continuous variable in days)
are minimal in particular for leucopaenia and neutro-
paenia. The respective adjusted risk (AOR) 95%CIs were
0.94-0.98 and 1.02-1.04.
WCC and leucopaenia
Leucopaenia was infrequent both at baseline and post-
treatment. White blood cells total counts without differ-
ential counts appear to be uninformative as they will
not capture larger variations in neutrophil counts that
are partly compensated by opposite variations in lym-
phocytes (not assessed here, but seen in under five years
old [24]). Baseline WCC counts were overall within the
normal ranges but conditions may vary; in one site
(Rukara, Rwanda) 30% of patients had leucopaenia pre-
treatment [15,17]. Post-treatment, WCC values
decreased minimally or remained constant and within
normal ranges resulting in a low frequency of leucopae-
nia (2%) occurring during follow-up, without significant
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lower risk, while higher baseline parasitaemia increased
the risk. WCC was not a good surrogate for
neutropaenia.
Neutrophil counts and neutropaenia
Baseline neutrophil counts were overall normal (6% neu-
tropaenia, consistent with 7% found in under five years
old [24]), but with wide variations across sites (30% in
Rukara, Rwanda [15]). There were fewer patients with
differential counts recorded post-treatment than patients
with total WCC (73% and 86% on Days 14, and 28,
respectively). Neutropaenia post-treatment was more
frequent than leucopaenia. No significant difference in
neutrophil counts was apparent between treatments
except for a greater drop (approximately by one-third)
by Day 14 with AS&AQ than with artemether-lumefan-
trine on Day 14, but Day 28 counts were not different.
Age appeared to protect against neutropaenia (here
like in [24]), but here there was no association between
neutropaenia and baseline parasitaemia or type of treat-
ment (while in under five years old the risk of neutro-
paenia was lower in case of higher baseline parasitaemia
and ACT treatment).
Haemoglobin and anaemia
Anaemia was frequent before treatment (around 60%,
on average, and up to 90% in Cameroon and Uganda-
Kampala) [14,16] and decreased significantly over time
after treatment in all groups. The net gain in haemoglo-
bin by Day 28 was consistently around 10% over the
baseline value with most of the treatments. Only artesu-
nate mono-therapy [13] and dihydroartemisinin-pipera-
quine by Day 14 [15] had a significantly lower gain than
with AS&AQ. With all treatments, patients with high
parasitaemia and parasitological reappearance during the
follow-up were at higher risk of anaemia, while older
age protected against anaemia irrespective of the parasi-
taemia (only the latter found in under five years old
[24]).
Artemisinin compounds have been shown to induce
reticulocytopaenia both in experimental and clinical
conditions potentially by suppressing erythroblasts and
that malaria itself could protect against reticulocytopae-
nia [25]. None of these studies reported reticulocyte
counts, and only three studies had a comparator without
artesunate (two vs amodiaquine alone and one vs amo-
diaquine plus SP). No clear indication results from these
studies. In two studies [5,17] the proportion of patients
recovering from anaemia by Day 28 was higher after
treatment with amodiaquine alone than when combined
with artesunate while the proportions of patients
becoming anaemic was not different; conversely, no
differences were seen between treatments combining
amodiaquine with artesunate or SP.
Platelets and thrombocytopaenia
Only two studies recorded platelets in Mali [13] and in
Uganda [14], so it is difficult to generalize. The preva-
lence of thrombocytopaenia decreased post-treatment
(from 32% pre-treatment to 9% on Day 14). A reduction
of the risk was observed up to Day 14 corresponding
with the upward trend in platelets counts observed in
[24]. Baseline parasitaemia did not affect platelets varia-
tions, but parasitological reappearance did, and there
was a treatment effect in both datasets. A smaller
increase in platelets corresponding to a greater risk of
thrombocytopaenia was observed in Uganda with AQ
+SP (p =0 . 0 4 0 )a n dA L( p =0 . 0 1 3 )c o m p a r e dt ot h e
A S & A Q ,w h i l en od i f f e r e n c eb e t w e e ng r o u p sw a s
detected in Mali.
Adverse events and treatment-related adverse events
Deviation of laboratory values from normality is graded
according to widely accepted severity criteria [23]; how-
ever, establishing causality (drug-event relationship) is
often a challenge for physicians. The incidence of
TEAEs was calculated in the subgroup of patients with
values on both Day 0 and post-treatment follow-up
through Day 28 (only Day 14 was available for platelets)
and found no difference between treatments for neutro-
paenia, and thrombocytopaenic but a higher risk of
TEAEs for anaemia with ACT than with non-artemisi-
nin combinations. TEAEs express more reliably the
deterioration of conditions as they exclude AEs, which
occurred already at the same intensity before treatment.
This analysis was also conservative, as all events, occur-
ring at any time post-treatment, were counted, irrespec-
tive of whether the parameter improved later on.
The size of this database (relatively large), the spectrum
representation (locations and ages) and the analyses done
(multivariate) are all positive features and advantages
over single-site papers or meta-analyses of aggregate
data. However, a note of caution is needed as to how to
interpret these results. The absence of a signal does not
mean that there is no risk, or certainty about no excess
risk (over other treatments). Rare events will require a
v e r yl a r g es a m p l es i z et h a tw a sn o ta v a i l a b l eh e r e .T h e
sample size is further reduced for individual variables (in
particular white blood cells differential counts, hence
neutropaenia); also, all variables were not assessed uni-
formly at the same time. There is also the issue of special
risk groups, such as HIV-coinfected subjects (high risk
for neutropaenia [7,8]) and pregnant women (potential
risk for reticulocytopaenia - reviewed in [25]), which are
not represented in the population under study here.
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